Clinical Trials Browser

Phase 1/2 × Stomach Neoplasms × balstilimab × Clear all

NCT05205330 2025-10-29

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Phase 1/2 Active not recruiting

Gastrointestinal

Stomach Neoplasms, Colorectal Neoplasms